TG Therapeutics/$TGTX
1D1W1MYTD1Y5YMAX
Capital at risk
About TG Therapeutics
TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.
- Ticker
- $TGTX
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 399
- Headquarters
- Morrisville, United States
- Website
- www.tgtherapeutics.com
TG Therapeutics Metrics
BasicAdvanced
$7.9B
20.17
$2.77
1.67
-
Price and volume
Market cap
$7.9B
Beta
1.67
52-week high
$59.30
52-week low
$26.76
Average daily volume
1.8M
Financial strength
Current ratio
4.267
Quick ratio
3.552
Long term debt to equity
1.246
Total debt to equity
1.249
Interest coverage (TTM)
3.64%
Profitability
EBITDA (TTM)
136.43
Gross margin (TTM)
82.37%
Net profit margin (TTM)
55.22%
Operating margin (TTM)
17.05%
Effective tax rate (TTM)
-334.54%
Revenue per employee (TTM)
$2,000,000
Management effectiveness
Return on assets (TTM)
7.28%
Return on equity (TTM)
100.28%
Valuation
Price to earnings (TTM)
20.171
Price to revenue (TTM)
9.955
Price to book
13.12
Price to tangible book (TTM)
13.57
Price to free cash flow (TTM)
457.824
Free cash flow yield (TTM)
0.22%
Free cash flow per share (TTM)
0.122
Growth
Revenue change (TTM)
76.08%
Earnings per share change (TTM)
667.52%
3-year revenue growth (CAGR)
221.54%
10-year revenue growth (CAGR)
135.50%
3-year earnings per share growth (CAGR)
29.65%
10-year earnings per share growth (CAGR)
8.20%
What the Analysts think about TG Therapeutics
Analyst ratings (Buy, Hold, Sell) for TG Therapeutics stock.
Analyst projections of the future price of TG Therapeutics stock.
Bulls say / Bears say
BRIUMVI U.S. net product revenue reached $227.7 million in Q2 2026, a ~64% year-over-year increase, demonstrating accelerating commercial traction (TG Therapeutics press release Aug 3, 2026) (TG Therapeutics)
Secured $500 million in net non-dilutive capital through an expanded $750 million senior credit facility and raised its share repurchase program to $300 million, enhancing financial flexibility and signaling management confidence (TG Therapeutics press release Mar 19, 2026) (TG Therapeutics)
Positive topline Phase 3 ENHANCE results demonstrated bioequivalent exposure with a consolidated single-infusion initiation regimen for BRIUMVI, potentially simplifying dosing and improving patient convenience (TG Therapeutics press release May 27, 2026) (TG Therapeutics)
Q2 EPS of $0.05 missed the $0.31 consensus by $0.26, highlighting near-term earnings volatility and investor concerns about profitability (MarketBeat) (MarketBeat)
Reported operating income and net income were limited by approximately $55 million of subcutaneous and secondary-source manufacturing charges in Q2, with ~$100 million expected for full-year 2026, pressuring margins (MarketBeat) (MarketBeat)
The new $750 million senior secured credit facility increases gross leverage, raising net non-dilutive debt by $500 million and potentially heightening interest obligations and refinancing risk (TG Therapeutics press release Mar 19, 2026) (TG Therapeutics)
Data summarised monthly by Lightyear AI. Last updated on 21 Aug 2026.
TG Therapeutics Financial Performance
Revenues and expenses
TG Therapeutics Earnings Performance
Company profitability
Upcoming events
No upcoming events
TG Therapeutics News
AllArticlesVideos
Funds containing TG Therapeutics
AllUSDEURGBP
Fund name | Fund size | $TGTX weighting |
|---|---|---|
iShares Healthcare Innovation$HEAL | $1.4B | 0.77% |
iShares Healthcare Innovation€2B78 | €1.2B | 0.77% |
iShares Healthcare Innovation£DRDR | £1B | 0.77% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.40% |
iShares S&P Small Cap 600£ISP6 | £2.4B | 0.40% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.